Deferred registration - ICON Clinical (UK) Limited/Newcastle Upon Tyne Hospitals NHS Foundation Trust Code: BP45361

ISRCTN ISRCTN10343007
DOI https://doi.org/10.1186/ISRCTN10343007
EU Clinical Trials Register (EudraCT) 2024-511110-21
Integrated Research Application System (IRAS) 1013710
Central Portfolio Management System (CPMS) 72779
Sponsor F. Hoffman-La Roche AG
Funder F. Hoffman-La Roche AG
Submission date
01/10/2026
Registration date
05/10/2026
Last edited
06/11/2026
Recruitment status
Recruiting
Overall study status
Deferred
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Contact information

Clinical Trial Accountable
Public, Scientific

Building 1
Grenzacherstrasse 124
Basel Town
CH-4070
Switzerland

Phone +1 (0)888 662 6728
Email global-roche-genentech-trials@gene.com
Prof Nicola Pavese
Principal investigator

The Newcastle upon Tyne Hospitals NHS Foundation Trust
Freeman Hospital
Freeman Road
High Heaton
Newcastle Upon Tyne
NE7 7DN
United Kingdom

Phone +44 (0)191 208 1264
Email nicola.pavese@newcastle.ac.uk

Study information

Primary study designInterventional
AllocationN/A: single arm study
MaskingOpen (masking not used)
ControlUncontrolled
AssignmentSingle
PurposePhase I trial examining safety, tolerability, pharmacokinetics, and pharmacodynamics
Scientific titleDeferred registration - ICON Clinical (UK) Limited/Newcastle Upon Tyne Hospitals NHS Foundation Trust Code: BP45361
Study objectives The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.
Ethics approval(s)

Approved 01/05/2026, Cambridge East Research Ethics Committee (2 Redman Place, Stratford, London, EC20 1JQ, United Kingdom; +44 (0)2071048181; cambridgeeast.rec@hra.nhs.uk), ref: 26/EE/0070

Health condition(s) or problem(s) studiedThe Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.
InterventionThe Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.
Intervention typeDrug
PhasePhase I
Drug / device / biological / vaccine name(s)The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.
Primary outcome measure(s)
  1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.
Key secondary outcome measure(s)
  1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.
Completion date11/05/2027

Eligibility

Participant type(s)
Age groupMixed
Lower age limit40 Years
Upper age limit75 Years
SexAll
Target sample size at registration30
Key inclusion criteriaThe Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.
Key exclusion criteriaThe Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.
Date of first enrolment20/10/2026
Date of final enrolment31/03/2027

Locations

Countries of recruitment

  • United Kingdom
  • England
  • Austria
  • Netherlands
  • Sweden

Study participating centres

The Newcastle upon Tyne Hospitals NHS Foundation Trust
Freeman Hospital
Freeman Road
High Heaton
Newcastle upon Tyne
NE7 7DN
England
University Hospitals Plymouth NHS Trust
Derriford Hospital
Derriford Road
Plymouth
Devon
PL6 8DH
England

Results and Publications

Individual participant data (IPD) Intention to shareNo

Editorial Notes

06/11/2026: Internal review.
01/10/2026: Study's existence confirmed by the HRA.